3Decaux G, Soupart A, Vassart G. Non - peptide arginine - vasopressin antagonists:the vaptans. Lancet,2008,371 (9624) : 1624.
4Hoom E J, Zietse R. Vasopressin - receptor antagonists. Future Cardiol,2010,6(4) :523.
5Steinwall M,Bossmar T,Gaud C,et al. Inhibitory effects of SR49059 on oxytocin and vasopressin induced uterine contractions in non - pregnant women. Acta Obstet Gynecol Scand,2004,83 :12.
6Steinwall M,Bossmar T,Brouard R,e? al. The effect of relcovaptan( SR 49059) ,an orally active vasopressin Via receptor antagonist,on uterine contraction in preterm labor. Gynecol Endocrinol, 2005 ,20 ( 2 ) : 104.
7Tahara A,Tsukada J,Tomura Y,et al. Effects of YM218 , a nonpeptide vasopressin VIA receptor - selective antagonist, on human vasopressin and oxytocin receptors. Pharmacol Res,2005 ,51 (3 ) :275.
8Ami^shieva A V,Ilnitskaya S I,Nikolin V P,et al. Effect of vasopres-
sin Vlb receptor antagonist, SSR149415 , on anxiety - like behavior and Lewis lung carcinoma metastasis in mice. Exp Oncol,2011,33(3) :126.
10Griebel G,Simiand J,Serradeil - he G C,et al. Anxiolytic - and antidepressant -like effects of the non - peptide vasopressin Vlb - receptor antagonist, SSR149415 , suggest an innovative approach for the treatment of stress - related disorders. Proc Natl Acad Sci USA,2002,99 (9): 6370.
